Pharming Group to Publish 2025 Results on March 12
Pharming Group N.V. announces that it will present its unaudited preliminary financial results for the fourth quarter and the full year of 2025 on Thursday, March 12, 2026, according to the press release. A conference call and webcast for analysts and investors are scheduled for the same day.
The Dutch biopharmaceutical group will disclose its preliminary financial results for the fourth quarter and the entire year of 2025 on March 12, 2026, the company states. A conference call and webcast are set for 1:30 PM Central European Time (8:30 AM New York Time) aimed at analysts and investors. Pre-registration is required to participate in the conference call or to follow the live webcast. Pharming notes that only telephone-connected participants will be able to ask questions during the event. The webcast will also be available on the company's website in the investor relations and financial documents section, and a recording will be posted shortly after the event.
Company Profile and Operations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Pharming Group N.V., listed on Euronext Amsterdam and the Nasdaq, identifies itself as a global biopharmaceutical company specializing in the development and marketing of treatments for patients suffering from rare, debilitating, and potentially life-threatening diseases, according to the press release. The group's portfolio of innovative drugs includes small molecules and biological products. The company is headquartered in Leiden, Netherlands, and employs a significant portion of its staff in the United States, the company indicates.
Registration Links and Additional Information
The registration links for the conference call and webcast are available in the press release issued this Thursday, February 26. Investors and analysts may register in advance to receive the connection details and a unique PIN code for accessing the event. For further information, Pharming refers to its website and provides contact details for investor relations and media relations. Michael Levitan, Vice President of Investor Relations and Corporate Communications, is the primary contact for investors. Media relations are handled by Saskia Mehring globally, Ethan Metelenis in the United States, and Leon Melens in the Netherlands.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 117,6 millions de dollars
Quarterly revenue: 117,6 millions de dollars
Revenue growth: 21 %
Guidance from the release
Tightened 2026 total revenue guidance to between US$380 million and US$390 million from prior US$375 million to US$395 million
Risks mentioned
Joenja revenue growth was partly driven by temporary benefit from ordering patterns in other international markets
RUCONEST third quarter revenue includes an early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer, following significant drawdowns earlier in the year
Napazimone (KL1333): enrollment in the pivotal FALCON trial now expected to complete in the first half of 2027 (about 145 of 180 subjects by end-2026), with topline results approximately one year after completion of enrollment
Opportunities identified
RUCONEST stabilization and continued recovery of demand in the US (third quarter revenue of about US$93.8 million, +14% year-on-year and +30% versus the second quarter of 2026)
Joenja strong growth driven by launches in Germany, Japan and continued penetration in the U.K.
Substantial growth potential for Joenja with estimated CVID with immune dysregulation prevalence of 39 patients per million vs 1.5 for APDS
Outlook / guidance
Expected revenue: 385 millions de dollars
Management commentary: Tightened 2026 total revenue guidance to between US$380 million and US$390 million (1% to 4% growth) from prior US$375 million to US$395 million (0% to 5% growth)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
